Crossject Stock

Crossject EBIT

The EBIT of Crossject (ALCJ.PA) as of Jul 16, 2026 is -12.96 M EUR. In the previous year, EBIT was -11.80 M EUR — a change of 9.85% (lower).

EBIT

-12.96 MEUR

YoY

9.85%

Last updated:

In 2026, Crossject's EBIT was -12.96 M EUR, a 9.85% increase from the -11.80 M EUR EBIT recorded in the previous year.

The Crossject EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M EUR)
Date
EBIT (M EUR)
Jan 1, 2020
-10.67 base
Jan 1, 2021
-11.82 base
Jan 1, 2022
-13.29 base
Jan 1, 2023
-11.80 base
Jan 1, 2024
-12.96 base
Jan 1, 2025 (e)
9.93 base
Jan 1, 2026 (e)
23.22 base
Jan 1, 2027 (e)
32.08 base
YEAREBIT (M EUR)
2027 est 32.08
2026 est 23.22
2025 est 9.93
2024 -12.96
2023 -11.80
2022 -13.29
2021 -11.82
2020 -10.67
2019 -8.64
2018 -11.56
2017 -8.62
2016 -7.29
2015 -7.01
2014 -5.11
2013 -2.62
2012 -1.42
2011 -1.85
2010 -4.43
Access this data via the Eulerpool API

Crossject Revenue

Crossject Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
0.00 EUR
-10.67 M EUR
-9.84 M EUR
Jan 1, 2021
912,000.00 EUR
-11.82 M EUR
-10.81 M EUR
Jan 1, 2022
954,000.00 EUR
-13.29 M EUR
-11.16 M EUR
Jan 1, 2023
145,000.00 EUR
-11.80 M EUR
-8.64 M EUR
Jan 1, 2024
0.00 EUR
-12.96 M EUR
-12.80 M EUR
Jan 1, 2025 (e)
44.48 M EUR
9.93 M EUR
4.15 M EUR
Jan 1, 2026 (e)
48.61 M EUR
23.22 M EUR
16.14 M EUR
Jan 1, 2027 (e)
65.87 M EUR
32.08 M EUR
21.88 M EUR

Crossject Margins

Crossject stock margins

The Crossject margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Crossject. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Crossject.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
1,885.52 %
- %
- %
Jan 1, 2021
604.28 %
-1,296.38 %
-1,184.87 %
Jan 1, 2022
724.21 %
-1,392.87 %
-1,169.50 %
Jan 1, 2023
1,885.52 %
-8,137.93 %
-5,957.24 %
Jan 1, 2024
1,885.52 %
- %
- %
Jan 1, 2025 (e)
1,885.52 %
22.31 %
9.32 %
Jan 1, 2026 (e)
1,885.52 %
47.76 %
33.19 %
Jan 1, 2027 (e)
1,885.52 %
48.70 %
33.21 %

Crossject Stock analysis

What does Crossject do? Crossject SA is a company that specializes in the development and manufacturing of innovative drug delivery systems. The company was founded in 2006 by a team of professionals with the goal of changing the way medications are administered. Crossject's history began with the development of a unique drug delivery system called ZENEO. This system is based on a proprietary technology called "Needle Free Injection" that allows for needle-free and painless medication administration. The technology is safe, easy to use, and enables the administration of liquid medications and even solids in the form of suspensions. Crossject specializes in the application of this technology and develops products in various areas, including adrenaline for the treatment of life-threatening allergic reactions, methotrexate for the treatment of cancer, and anti-inflammatory medications for the treatment of asthma and COPD. The business model of Crossject is based on the development and commercialization of products based on the ZENEO technology. The company collaborates with a range of partners to bring its products to market, including pharmaceutical companies and other drug manufacturers. Crossject aims to sell its products worldwide and already has distribution partners in various countries around the world. Crossject is also committed to advancing the development of new products based on this technology. The company invests a significant portion of its revenue in research and development and works closely with academic institutions and other research facilities to improve its technology and products. Crossject's product offering includes a wide range of medications used for the treatment of various conditions. One example is the adrenaline injection system developed for the rapid and effective treatment of anaphylactic shocks that can occur as severe allergic reactions in people with food allergies, insect venom allergies, or drug allergies. The system does not require a needle and is therefore easy and safe to handle. Another example is the methotrexate injection for the treatment of cancer and autoimmune diseases such as rheumatoid arthritis and psoriasis. Crossject has also developed a range of products to combat asthma and chronic obstructive pulmonary disease (COPD). In 2019, the company received regulatory approval for its first commercial ZENEO product as an emergency treatment for migraines. This product is a fast-acting migraine therapy that is administered subcutaneously to quickly and effectively relieve pain and accompanying symptoms of migraines. In summary, Crossject is an innovative company specializing in the development and commercialization of drug delivery systems. The company utilizes a proprietary technology that allows for needle-free and painless medication administration and collaborates closely with partners to sell its products worldwide. Crossject continues to invest in research and development to bring new products based on its technology to market and establish itself as a leading company in its field. Crossject is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Crossject's EBIT

Crossject's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Crossject's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Crossject's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Crossject’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Crossject stock

EBIT of Crossject is -12.96 M EUR in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Crossject

All Key Metrics — Crossject